Cellosaurus cell line SP-53 (CVCL_C122)

PubMed=2548699; DOI=10.1002/1097-0142(19890915)64:6<1248::AID-CNCR2820640614>3.0.CO;2-5
Daibata M., Kubonishi I., Eguchi T., Yano S., Ohtsuki Y., Miyoshi I.
The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B) and Epstein-Barr virus nuclear antigen-negative (SP-53) cell lines with t(11;14)(q13;q32) chromosome abnormality from an intermediate lymphocytic lymphoma.
Cancer 64:1248-1253(1989)

PubMed=8971032; DOI=10.1128/JVI.70.12.9003-9007.1996
Daibata M., Kubonishi I., Miyoshi I.
Differential tumorigenicity between Epstein-Barr virus genome-positive and genome-negative cell lines with t(11;14)(q13;q32) derived from mantle cell lymphoma.
J. Virol. 70:9003-9007(1996)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=11061568; DOI=10.18926/AMO/32293
Jin Z., Teramoto N., Yoshino T., Takada K., Oka T., Hayashi K., Akagi T.
Characterization of Epstein-Barr virus-infected mantle cell lymphoma lines.
Acta Med. Okayama 54:193-200(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=12683869; DOI=10.5858/2003-127-0424-COMCLC
Amin H.M., McDonnell T.J., Medeiros L.J., Rassidakis G.Z., Leventaki V., O'Connor S.L., Keating M.J., Lai R.
Characterization of 4 mantle cell lymphoma cell lines. Establishment of an in vitro study model.
Arch. Pathol. Lab. Med. 127:424-431(2003)

PubMed=16960149; DOI=10.1182/blood-2006-06-026500
Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F., Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Blood 109:271-280(2007)

PubMed=26194763; DOI=10.1182/blood-2015-01-624585
Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y., Isik E., Letai A.G., Lossos I.S.
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.
Blood 126:1555-1564(2015)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)